Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab
- Abstract
- Purpose: The tumor-infiltrating lymphocytes (TILs) expression in breast cancer is a positive prognostic marker for certain breast cancer subtypes. We evaluated the efficacy of dual antihuman epidermal growth factor receptor 2 (HER2) blockade in HER2-positive breast cancer and hypothesized that high TILs tumors are associated with better outcomes.
Methods: A total of 176 patients who were treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) between December 2015 and December 2018 were reviewed. They were grouped based on a cut-off value of the stromal TILs grade (<= 20% TILs, > 20% TILs).
Results: In total, 107 patients (60.8%) achieved pathological complete response (pCR). Hormone receptor (HR)-negativity (p = 0.001) and a high TILs grade (p = 0.022) were independent predictors of pCR. Among the HR-negative patients, high TILs tumors were significantly associated with pCR (p = 0.035).
Conclusion: HR status and the TILs grade are significantly correlated with pCR in dual anti-HER2 neoadjuvant therapy. The evaluation of the TILs at baseline may be beneficial for predicting pCR in HER2-positive breast cancer.
- Author(s)
- 고범석; 공경엽; 김성배; 김정은; 김학희; 안진희; 이희진; 정경해; 정일용; 정재호; 채은영; 하주영
- Issued Date
- 2021
- Type
- Article
- Keyword
- Receptor; ErbB-2; Neoadjuvant therapy; Lymphocytes; Tumor microenvironment
- DOI
- 10.4048/jbc.2021.24.e36
- URI
- https://oak.ulsan.ac.kr/handle/2021.oak/8143
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_9856025&context=PC&vid=ULSAN&lang=ko_KR&search_scope=default_scope&adaptor=primo_central_multiple_fe&tab=default_tab&query=any,contains,Tumor-Infiltrating%20Lymphocytes%20in%20Human%20Epidermal%20Growth%20Factor%20Receptor%202-Positive%20Breast%20Cancer%20Receiving%20Neoadjuvant%20Docetaxel,%20Carboplatin,%20Trastuzumab,%20and%20Pertuzumab&offset=0&pcAvailability=true
- Publisher
- JOURNAL OF BREAST CANCER
- Location
- 대한민국
- Language
- 영어
- ISSN
- 1738-6756
- Citation Volume
- 24
- Citation Number
- 4
- Citation Start Page
- 359
- Citation End Page
- 366
-
Appears in Collections:
- Medicine > Medicine
- Authorize & License
-
- Files in This Item:
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.